Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.…
Lexicon Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London
Lexicon Pharmaceuticals (NASDAQ: LXRX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 81 employees.
The shares were at 1.530 USD on 20 November 2026, up 22.4% over 52 weeks. Its 52-week range is 1.100 USD to 2.680 USD: the price is 42.9% below the high and 39.1% above the low.
Its market capitalisation is 681.21M USD.
Lexicon Pharmaceuticals reports return on equity of -46.8%, an operating margin of -147.4% and revenue down 20.7% year over year.
It holds more cash than debt, a net cash position of 123.67M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 6 analysts cover the stock, with an average rating of Buy; their mean price target of 4.515 USD is 195.1% above the current price. The next earnings report is expected on 4 March 2027.